13968-h20b (Sino Biological)
Structured Review
13968 H20b, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ror1/Human+ROR1+Protein/pmc13098526-16-0-4
Average 94 stars, based on 4 article reviews
Images
Related Articles
other:Article Title: Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer. Article Snippet: As a kind of pseudokinase, although ROR1 lacks the ATP catalytic activity similar to that of classical kinases, it has been proven to play a crucial role in the occurrence and development of triple-negative breast cancer (TNBC).. Through structure-based drug design strategy, we have discovered novel quinolin-2-amine ROR1 inhibitor 59 which exhibited excellent binding activity to ROR1 (KD = 0.052 μM) and antiproliferative against breast cancer cells in vitro (IC50 = 0.075 μM) while maintaining good selectivity through kinase profiling screening.. Mechanistic studies confirmed 59 could induce cell apoptosis and suppresses ROR1 phosphorylation. Injection:Article Title: Novel macromolecule CPD4 suppresses cell proliferation and metastasis of triple-negative breast cancer by targeting ROR1 protein. Article Snippet: Breast cancer is the second most common cancer among women in the US, with triple-negative breast cancer (TNBC) accounting for 15–20 % of new diagnoses.. TNBC cells lack estrogen and progesterone receptors, and human epidermal growth factor receptor 2, which makes them resistant to standard hormone treatments.. Current therapies like chemotherapy and radiation often harm both cancerous and healthy cells, underscoring the need for developing new targeted treatments. |


